心境稳定剂单药或联合治疗对双相躁狂患者外周血单核细胞糖原合成酶激酶3活性的影响

doi:10.3969/j.issn.1006-7795.2016.02.010

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (2): 158-163.doi: 10.3969/j.issn.1006-7795.2016.02.010

心境稳定剂单药或联合治疗对双相躁狂患者外周血单核细胞糖原合成酶激酶3活性的影响

李晓虹¹, 蔡焯基², 刘敏³, 王刚^2,4

1. 首都医科大学附属北京安定医院4区, 北京 100088;
2. 首都医科大学附属北京安定医院抑郁症治疗中心, 北京 100088;
3. 首都医科大学北京安定医院疾病资源库, 北京 100088;
4. 国家精神心理疾病临床医学研究中心北京脑重大疾病研究院抑郁症研究所, 北京 100088

收稿日期:2016-01-20 出版日期:2016-04-21 发布日期:2016-04-14
通讯作者: 李晓虹, 王刚 E-mail:lxhshy2002@163.com;gangwangdoc@gmail.com
基金资助:
国家临床重点专科建设项目

Effect of treatment with different mood stabilizers on glycogen synthase kinase-3 activity in the peripheral blood mononuclear cells of patients with bipolar mania

Li Xiaohong¹, Cai Zhuoji², Liu Min³, Wang Gang^2,4

1. Ward No. 4 of Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
2. Mood Disorders Center, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
3. Disease Resource Library Center, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
4. National Clinical Research Center for Mental Disorders;Center of Depression, Beijing Institute for Brain Disorders, Beijing 100088, China

Received:2016-01-20 Online:2016-04-21 Published:2016-04-14
Supported by:
This study was supported by National Clinical Key Specialty Construction Project.

摘要/Abstract

摘要： 目的探讨不同心境稳定剂单药或联合非典型抗精神病药物治疗对双相躁狂患者外周血单核细胞(peripheral blood mononuclear cells, PBMCs)糖原合成酶激酶3(glycogen synthase kinase 3, GSK3)活性的影响。方法纳入双相I型躁狂发作患者36例,给予碳酸锂或丙戊酸钠联合非典型抗精神病药物8周。分别于基线、4周和8周末采集患者外周静脉血20 mL,应用免疫印迹法检测患者PBMCs的GSK3α和GSK3β丝氨酸磷酸化水平(pSer-GSK3α,pSer-GSK3β)以及总GSK3水平(total-GSK3α和total-GSK3β)。采用杨氏躁狂量表(Young Mania Ratings Scale,YMRS)和临床症状严重度量表(Clinical Global Impression-Scale,CGI-S)等评估症状变化。结果治疗8周,各组患者的YMRS、CGI-S等评分均明显降低(P<0.001),与此同时,治疗后PBMCs的pSer-GSK3α、pSer-GSK3β较治疗前明显升高;不同心境稳定剂组间比较,pSer-GSK3β/total-GSK3β相对比值差异存在统计学意义(P=0.020),锂盐组变化明显(P=0.024);相关分析显示,pSer9-GSK3β/total-GSK3β比值与4周末YMRS减分绝对值呈负相关(r=-0.413,P=0.043)。剔除反复躁狂发作(≥3次)患者,这一趋势更加显著(r=-0.543,P=0.020)。其中锂盐组呈现了相似的变化(r=-0.432,P=0.083),而丙戊酸钠组无。结论心境稳定剂单药或联合非典型抗精神病药物治疗可降低双相躁狂患者PBMCs的GSK3活性,碳酸锂单药或联合治疗相比丙戊酸钠,可以更显著降低双相躁狂患者的GSK3活性。

关键词: 双相障碍, 躁狂发作, 心境稳定剂, 锂盐, 丙戊酸盐, 非典型抗精神病药, 糖原合成酶激酶3

Abstract: Objective To explore the therapeutic effects of of different mood stabilizers single or combined atypical antipsychotics on glycogen synthase kinase 3 (GSK3) activity in the peripheral blood mononuclear cells (PBMCs) of patients with bipolar mania. Methods Thirty-six patients with bipolar I mania were enrolled for treatment with mood stabilizers single or combined atypical antipsychotics for eight weeks. Twenty mL of blood was collected from each patient by venipuncture at week 0, week 4 and week 8. The level of pSer21-GSK3α;pSer9-GSK3β, total GSK3α and GSK3β in PBMCs of patients were measured by Western blotting. Clinical symptoms were assessed with the Young mania ratings scale (YMRS) and other clinical rating scales at the same time. Results The average scores of YMRS, and CGI-S significantly reduced at week 8 compared with those at week 0 (P<0.001); meanwhile, the level of pSer21-GSK3α and pSer9-GSK3β increased at week 8; Compared with valproate group, the relative ratio of pSer-GSK3β/total-GSK3β was higher than that of lithium group (P=0.020). There was a positive correlation between ratio of pSer9-GSK3β to toal-GSK3β at baseline and the average score of YMRS reduction from baseline to week 0 (P=0.043). Excluding patients with manic episodes more than 3 times, there was a significant trend of increase (P=0.020). The correlation was significant in lithium group. However, it did not appear in valproate group. Conclusion Mood stabilizers single or combined atypical antipsychotics could decrease glycogen synthase kinase 3 (GSK3) activity in the peripheral blood mononuclear cells (PBMCs) of patients with bipolar mania. Compared with valproate treatment, lithium single or combined treatment could significantly reduce the activity of GSK3 of patients with bipolar mania.

Key words: bipolar disorder, manic episode, mood stabilize, lithium, valproate, atypical antipsychotic, glycogen synthase kinase 3

中图分类号:

R749.05

李晓虹, 蔡焯基, 刘敏, 王刚. 心境稳定剂单药或联合治疗对双相躁狂患者外周血单核细胞糖原合成酶激酶3活性的影响[J]. 首都医科大学学报, 2016, 37(2): 158-163.

Li Xiaohong, Cai Zhuoji, Liu Min, Wang Gang. Effect of treatment with different mood stabilizers on glycogen synthase kinase-3 activity in the peripheral blood mononuclear cells of patients with bipolar mania[J]. Journal of Capital Medical University, 2016, 37(2): 158-163.

参考文献

[1] Jope R S, Roh M S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions[J]. Curr Drug Targets, 2006, 7(11):1421-1434.
[2] Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3β:a putative model of hyperactivity and mania[J]. J Neurosci, 2006, 26(35):9022-9029.
[3] 李晓虹,刘敏,罗小年,等. 糖原合成酶激酶3与双相情感障碍[J]. 首都医科大学学报, 2008,29 (4):436-439.
[4] 李晓虹, 蔡焯基, 刘敏,等. 碳酸锂联合奥氮平对双相躁狂患者外周血单核细胞糖原合成酶激酶3活性的影响[J].临床精神医学杂志, 2011,21(6):415-419.
[5] American Psychiatric Association. Diagnostic and statistic manual of mental disorders[M]. Washington, DC:American Psychiatric Press, Inc.,2000.
[6] Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding[J]. Anal Biochem, 1976, 72:248-254.
[7] J·萨姆布鲁克,E·F弗里奇,T·曼尼阿蒂斯. 分子克隆实验指南[M]. 黎孟枫等译. 2版. 北京:科学出版社, 1992:872-968.
[8] Grimes C A, Jope R S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling[J]. Prog Neurobiol, 2001, 65(4):391-426.
[9] Jope R S, Johnson G V. The glamour and gloom of glycogen synthase kinase-3[J]. Trends Biochem Sci, 2004, 29(2):95-102.
[10] Mai L, Jope R S, Li X. BDNF-mediated signal transduction is modulated by GSK3 and mood stabilizing agents[J]. J Neurochem, 2002, 82(1):75-83.
[11] 付华斌, 赵彩霞,罗克勇,等.心境稳定剂的临床应用进展[J]. 解放军医药杂志, 2013,25(2):56-58.
[12] 王健,王刚,马辛. 小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究[J]. 首都医科大学学报,2014,35(2):205-209.
[13] De Sarno P, Li X, Jope R S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium[J]. Neuropharmacology, 2002, 43(7):1158-1164.
[14] Stambolic V, Ruel L, Woodgett J R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells[J]. Curr Biol,1996, 6(12):1664-1668.
[15] Zhang F, Phiel C J, Spece L, et al. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK) in response to lithium. Evidence for autoregulation of GSK-3[J]. J Biol Chem,2003, 278(35):33067-33077.
[16] Chen G, Huang L D, Jiang Y M, et al. The mood-stabilizing agent valprovate inhibits the activity of glycogen synthase kinase-3[J]. Jf Neurochem,1999, 72(2):1327-1330.
[17] Grimes C A, Jope R S. CREB DNA binding activity is inhibited by glycogen synthase-3β and facilitated by lithium[J]. J Neurochem, 2001, 78(6):1219-1232.
[18] Li X, Liu M, Cai Z, et al. Regulation of glycogen synthase kinase-3 during bipolar mania treatment[J]. Bipolar Disorders, 2010, 12(7):741-752.

心境稳定剂单药或联合治疗对双相躁狂患者外周血单核细胞糖原合成酶激酶3活性的影响

Effect of treatment with different mood stabilizers on glycogen synthase kinase-3 activity in the peripheral blood mononuclear cells of patients with bipolar mania

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	刘珊珊, 房萌, 朱虹, 尹冬青, 赵燕, 赵爽, 贾竑晓. 2010年和2019年双相情感障碍住院患者的临床特征和未治疗持续时间的因素分析[J]. 首都医科大学学报, 2022, 43(3): 415-420.
[2]	李雪, 朱虹, 房萌, 宁艳哲, 赵爽, 尹冬青. 腹针治疗非典型抗精神病药物所致肥胖的治疗效果观察[J]. 首都医科大学学报, 2020, 41(1): 75-79.
[3]	王健, 王刚, 马辛. 小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究[J]. 首都医科大学学报, 2014, 35(2): 205-209.
[4]	贾竑晓, 尹梦雅, 朱虹. 躁狂发作患者的自我面孔识别速度研究[J]. 首都医科大学学报, 2013, 34(2): 204-206.
[5]	李晓虹;刘敏;罗小年;王刚. 糖原合成酶激酶3与双相情感障碍[J]. 首都医科大学学报, 2008, 29(4): 436-439.